Cardiff business receives equity from Finance Wales
AssayMetrics to commercialise prototype plate reader for use in the pharmaceutical and biotechnology industries
The early stage business has also received investment from a syndicate of business angels.
Dr Pierre Graves formed AssayMetrics in 2004. The following year, two senior scientists, Dr John Whateley and Dr Anthony Smith, joined the company.
In 2006 the company launched its chemical dye reagents, which are used in the biotechnology and pharmaceutical industries for compound screening. It subsequently developed its own Puretime novel fluorescent dye reagents before embarking on the development of a prototype plate reader, which added analytical instrumentation to its dye-based products.
According to AssayMetrics, a number of customers have expressed a wish to act as beta test sites for this plate reader.
‘The drug discovery market continues to grow despite the recession and we are delighted to be able to place a technology in the hands of customers that will make the process faster and more efficient,’ said Graves, chief executive of Assaymetrics.
Finance Wales provides commercial funding to small and medium-sized businesses throughout Wales, enabling them to realise their potential for innovation and growth.
A subsidiary of the Welsh Assembly Government, Finance Wales manages funds of more than £280m and has invested more than £157m in Wales-based businesses.
You may also like
Trending Articles
You may also like
Manufacturing
![SCHOTT Pharma launches EVERIC lyo & amber vials for light-sensitive ADCs]()
SCHOTT Pharma launches EVERIC lyo & amber vials for light-sensitive ADCs
Featuring the well-known EVERIC® lyo coating, EVERIC® lyo & amber is designed for lyophilised, light-sensitive antibody-drug-conjugates (ADCs). It offers reliable light protection at the primary packaging level, already during the fill-and-finish process. EVERIC amber is the first specialty vial for highly light-sensitive medications that simultaneously meets regulatory light transmission requirements in the EU, the U.S., and Japan
You need to be a subscriber to read this article.
Click here to find out more.
Click here to find out more.
Manufacturing
![Portable gas detection in the pharmaceutical sector]()
Portable gas detection in the pharmaceutical sector
Gas safety is a critical consideration in the pharmaceutical sector. Hazardous gases and airborne contaminants are common by-products of manufacturing processes … and employers must control worker exposure in accordance with relevant legislation and industry standards
Manufacturing
![New legal duties for QPs in decentralised manufacturing]()
New legal duties for QPs in decentralised manufacturing
In this clip, Dr. Peter Gough explains that QPs will be responsible for supervising decentralised activities, conducting regular audits, carrying out periodic on-site visits, confirming GMP compliance to regulatory authorities and notifying changes that may affect quality or safety
Manufacturing
![FDA escalates action against Dabur India over systemic data-integrity and cGMP failures]()
FDA escalates action against Dabur India over systemic data-integrity and cGMP failures
The US FDA has issued a warning letter to Dabur India following an inspection that identified falsified records, missing laboratory data, inadequate cleaning and process validation and weaknesses in quality-unit oversight, saying the company's response failed to address the systemic nature of the deficiencies
Manufacturing
![DNA Script and GE Healthcare awarded $26m ARPA-H funding to scale cell-free DNA bioproduction]()
DNA Script and GE Healthcare awarded $26m ARPA-H funding to scale cell-free DNA bioproduction
The pair will combine DNA Script's EDS technology with GE HealthCare's DNA scaling technology to create a faster, more flexible manufacturing process for cell-free DNA as the use of personalised and time-sensitive genetic medicines grows